<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399214</url>
  </required_header>
  <id_info>
    <org_study_id>IOP-CT-002</org_study_id>
    <nct_id>NCT03399214</nct_id>
  </id_info>
  <brief_title>Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects</brief_title>
  <official_title>A Phase Ib Study to Evaluate Safety and Efficacy Profiles of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MegaPro Biomedical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MegaPro Biomedical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the dose dependent changes in MRI signal intensity
      (SI) in liver after IOP Injection intravenous administration in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change of MRI SI (%) in vessels, liver, and spleen</measure>
    <time_frame>Day1: within 60 mins after IOP administration</time_frame>
    <description>The optimal imaging time of IOP injection for the maximum SI (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes from baseline in hematology data</measure>
    <time_frame>within 14 days</time_frame>
    <description>Complete blood count and differential count, Reticulocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of all treatment-related adverse events (TRAE)</measure>
    <time_frame>within 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>IOP Injection, Phase 1b, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV injection, 0.27 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IOP Injection, Phase 1b, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV injection, 0.54 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IOP Injection</intervention_name>
    <description>T1 and T2</description>
    <arm_group_label>IOP Injection, Phase 1b, Cohort 1</arm_group_label>
    <arm_group_label>IOP Injection, Phase 1b, Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male, age â‰¥ 20 ~40 years, BMI=18~27.

          2. The biochemistry test results, complete blood count (CBC) test results, urinalysis
             test results, coagulation time test results must within normal range or considered
             clinically normal by the clinical investigator at screening.

          3. Male subjects must take reliable contraceptive method(s) during and after the study
             for a period of 14 days.

          4. No screening of drug or alcohol abuse within one year prior to study enrollment.

          5. Subjects are willing to comply with the protocol and sign informed consent form.

        Exclusion Criteria:

          1. Subjects have serious allergic history or known allergy to MRI contrast agent.

          2. Subjects with HBV, HCV, HIV.

          3. Imaging and/or functional abnormalities of liver and/or spleen.

          4. Subjects have alcohol or caffeine consumption within 48 hours prior to the
             administration of study contrast agent.

          5. Subjects have electronically, magnetically and mechanically activated implanted
             devices.

          6. Subjects have participated in other investigational trials or receive any contrast
             agents within 28 days prior to study enrollment.

          7. Subjects with active systemic infections, active and clinically significant cardiac
             diseases, active gastrointestinal ulcers, or medical conditions that may significantly
             affect action, adequate absorption and elimination of investigational contrast agent.

          8. Subjects have taken any food 6 hours prior to administration.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rheun-Chuan Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>rclee@vghtpe.gov.tw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cherry Lo, MS</last_name>
    <phone>+886-3-5910360</phone>
    <phone_ext>271</phone_ext>
    <email>cherrylo@megaprobio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Wang, MD</last_name>
    <phone>+886-3-5910360</phone>
    <phone_ext>270</phone_ext>
    <email>idwang@megaprobio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei county</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rheun-Chuan Lee, MD</last_name>
      <phone>+886-2-28712121</phone>
      <phone_ext>3069</phone_ext>
      <email>rclee@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

